Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + capecitabine with stereotactic radiotherapy for advanced pancreatic cancer
ChiCTR-ONC-13003720Phase 2Completed
- Sponsor
- Army Specialized Medical Center
- Start
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar and capecitabine in pancreatic cancer (PC), sponsored by Army Specialized Medical Center. Primary endpoint: Progression-free survival. Started Oct 2013; status: completed.
02
Drugs
endostarcapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR-ONC-13003720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-13003720.